RE:Numbers August 28thMy 5 cents: DOC has yet to prove that the market wants what it has. Their sales are enemic, local
or regional small deals. On one hand, cutting costs and getting to profit is nice but the bigger question is, can they scale via big north american deals? There has yet to be any evidence that all the changes Karen has made are paying off. Last: I havent a clue if what DOC has/is is materially different than its competitors. I get a sense that they arent, or at least arent compelling enough for major corps to make a change from their encumbent